Geode Capital Management’s Acurx Pharmaceuticals ACXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $74.8K | Sell |
7,320
-1,254
| -15% | -$12.8K | ﹤0.01% | 4135 |
|
|
2025
Q1 | $66.9K | Buy |
8,574
+1,249
| +17% | +$9.74K | ﹤0.01% | 4135 |
|
|
2024
Q4 | $119K | Hold |
7,325
| – | – | ﹤0.01% | 4055 |
|
|
2024
Q3 | $278K | Buy |
7,325
+824
| +13% | +$31.3K | ﹤0.01% | 3795 |
|
|
2024
Q2 | $293K | Buy |
6,501
+683
| +12% | +$30.7K | ﹤0.01% | 3781 |
|
|
2024
Q1 | $285K | Buy |
5,818
+211
| +4% | +$10.3K | ﹤0.01% | 3813 |
|
|
2023
Q4 | $430K | Buy |
5,607
+1,177
| +27% | +$90.2K | ﹤0.01% | 3669 |
|
|
2023
Q3 | $127K | Buy |
4,430
+566
| +15% | +$16.2K | ﹤0.01% | 4164 |
|
|
2023
Q2 | $205K | Hold |
3,864
| – | – | ﹤0.01% | 4031 |
|
|
2023
Q1 | $267K | Hold |
3,864
| – | – | ﹤0.01% | 3912 |
|
|
2022
Q4 | $307K | Buy |
3,864
+52
| +1% | +$4.13K | ﹤0.01% | 3878 |
|
|
2022
Q3 | $228K | Buy |
3,812
+3,235
| +561% | +$193K | ﹤0.01% | 4126 |
|
|
2022
Q2 | $43K | Buy |
577
+30
| +5% | +$2.24K | ﹤0.01% | 4806 |
|
|
2022
Q1 | $35K | Buy |
+547
| New | +$35K | ﹤0.01% | 4872 |
|